Details for Patent: 7,982,043
Summary for Patent: 7,982,043
| Title: | Protein tyrosine kinase enzyme inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Allan Wissner, Sridhar Krishna Rabindran, Hwei-Ru Tsou | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Wyeth LLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US12/136,357 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,982,043 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 7,982,043: Claim Scope, Enforceability, and Patent LandscapeU.S. Patent No. 7,982,043 contains a narrow method-of-treatment claim directed to administering one specifically identified quinoline derivative, or a pharmaceutically acceptable salt, to treat or inhibit breast-cancer growth in a mammal. The claim does not cover the compound as a composition of matter, other cancers, or all kinase inhibitors. Its commercial value depends on the related composition, formulation, manufacturing, and method-of-use patents in the same patent family. What does U.S. Patent 7,982,043 claim?Claim 1 covers the following elements:
The claim is an apparatus-independent method claim. It is infringed, if otherwise valid and enforceable, by carrying out the claimed administration method. It does not require a particular formulation, dosage strength, route of administration, treatment duration, disease stage, biomarker, or combination partner. The active compound is:
The claim’s “selected from” language does not materially broaden the claim because only one compound is listed. The alternative covered chemical forms are the neutral compound and pharmaceutically acceptable salts. How narrow is the breast-cancer treatment claim?The claim is narrow in chemical identity but broad in clinical implementation. Chemical limitationsA practicing party must administer the specifically recited molecule or a pharmaceutically acceptable salt. A structurally related analog with a different substituent, stereochemistry, linker, or heteroaryl group would generally fall outside the literal chemical limitation unless the patent’s other claims or the doctrine of equivalents applies. The following changes could be material:
Whether a salt falls within the claim depends on whether it is a pharmaceutically acceptable salt of the same active compound. The claim does not expressly identify particular counterions, such as hydrochloride, mesylate, fumarate, maleate, or sulfate. Disease limitationThe claim is limited to breast cancer. Administration for renal-cell carcinoma, lung cancer, colorectal cancer, ovarian cancer, glioblastoma, or another cancer would not literally satisfy the disease limitation, even if the compound has anticancer activity in those diseases. The claim does not limit breast cancer by:
That breadth increases the method claim’s potential coverage against clinical use, but it also creates validity and enablement issues if the patent specification does not support the full breadth of breast-cancer treatment. What is the likely infringement exposure under Claim 1?A product or clinical program has the highest exposure when all of the following conditions are present:
A generic or follow-on manufacturer could face direct method-of-use risk if its labeling instructs treatment of breast cancer. A manufacturer may face induced-infringement allegations if it markets the drug with instructions that encourage physicians to perform the claimed method. A product sold for a non-breast-cancer indication presents a different risk profile. The principal questions would be whether the label contains breast-cancer instructions, whether the manufacturer actively promotes that use, and whether substantial use of the product is for the patented method. The claim does not require monotherapy. Combination treatment can satisfy the claim if the patented compound is administered in an effective amount for breast cancer. The claim also does not exclude prior or concurrent treatment with chemotherapy, endocrine therapy, radiation, immunotherapy, or another targeted agent. What does “effective amount” add to the claim?“Effective amount” is a functional limitation. The administered quantity must be sufficient to produce the claimed therapeutic result, treating breast cancer or inhibiting its growth. The claim does not specify:
In litigation, the specification and prosecution history would be important in determining how “effective amount” is construed. The term generally does not require a cure. Inhibition of tumor growth may be sufficient if supported by the patent’s disclosure and the facts of the accused use. Does Claim 1 cover the compound itself?No. Claim 1 is a method claim. It does not, by itself, prevent a party from:
Separate composition-of-matter, pharmaceutical-composition, formulation, process, salt, polymorph, or broader method claims would be required to create those forms of protection. The patent may contain additional claims, but the supplied text is insufficient to attribute broader protection to Patent 7,982,043. Claim analysis should therefore distinguish the supplied claim from the patent’s complete claim set. What related patents are likely to matter?A commercial patent estate for this type of kinase inhibitor would normally divide into several layers:
The composition patent generally has the greatest leverage because a generic manufacturer cannot avoid it merely by changing the label. A method claim such as Claim 1 has narrower enforcement reach but can still block a breast-cancer label or create litigation risk for a product whose commercial use is concentrated in breast cancer. When does U.S. Patent 7,982,043 lose exclusivity?Patent expiration cannot be determined from Claim 1 alone. The controlling calculation requires the patent’s earliest effective nonprovisional filing date, priority chain, patent-term adjustment, terminal disclaimers, and any patent-term extension. U.S. patent term is generally governed by 35 U.S.C. § 154 and runs 20 years from the relevant earliest nonprovisional filing date, subject to statutory adjustments.[1] The patent issued on July 19, 2011. Issuance date is not the expiration date. A continuation or divisional relationship can produce a patent with the same effective term as an earlier family member, while a later-filed continuation may have a different term only in limited circumstances. Terminal disclaimers can also tie the patent to another patent’s expiration date. For a freedom-to-operate review, the relevant timeline must include:
A patent’s expiration also does not eliminate later-expiring patents covering formulations, salts, polymorphs, dosing regimens, or approved methods. What is the Orange Book status of the claimed compound?Orange Book status cannot be inferred from the patent claim alone. The FDA Orange Book lists patents submitted by an NDA holder for an approved drug product, not every patent that claims a drug compound or its use.[2] The key questions are:
If the compound has no approved NDA, there is no Orange Book-listed product patent for that compound. Patent rights can still exist outside the Orange Book, including for preclinical development, nonapproved uses, manufacturing, and contractual licensing. What Paragraph IV challenges could affect this patent?An ANDA applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product.[3] For a breast-cancer method claim, the main challenge theories would include:
The risk of a Paragraph IV challenge is highest when the patent is listed in the Orange Book and its remaining term is commercially significant. A method patent generally creates less product-wide exposure than a composition patent because a generic applicant may attempt a section viii carve-out for an unpatented use, subject to the FDA’s labeling rules.[4] Which companies could challenge the patent?Potential challengers would include generic pharmaceutical companies with the manufacturing capacity to produce the active ingredient or a therapeutically equivalent product. Typical ANDA litigants in oncology products include companies such as Teva, Sandoz, Sun Pharma, Lupin, Dr. Reddy’s, Cipla, Aurobindo, Zydus, and Amneal. No company should be treated as a confirmed challenger without a filed Paragraph IV notice, a complaint under the Hatch-Waxman Act, an FDA Orange Book record, or a public settlement or litigation docket. The patent number and supplied claim do not establish that any particular company has challenged Patent 7,982,043. How strong is the patent estate?The supplied claim has moderate strength as an indication-specific enforcement tool and limited strength as a standalone product barrier. Strengths
Weaknesses
Commercial strength therefore depends on the broader family. A composition patent, an Orange Book-listed method patent, a later formulation patent, and regulatory exclusivity would create materially stronger protection than Claim 1 standing alone. What is the competitive and commercial significance?A breast-cancer method claim is commercially meaningful when the active compound has a breast-cancer label and the indication represents a major share of expected sales. Its value declines when:
The claim does not establish revenue exposure, market share, regulatory approval, or commercial launch. Those metrics require separate FDA, company, clinical-trial, and financial records. Key Takeaways
FAQsDoes Patent 7,982,043 cover all salts of the compound?It covers pharmaceutically acceptable salts of the specifically identified compound. The claim does not expressly enumerate each counterion, so salt status would depend on chemical identity and pharmaceutical acceptability. Can a company sell the compound for a different cancer indication?Claim 1, by itself, is limited to breast cancer. Separate claims, patents, labeling, promotional conduct, or related family members could create additional exposure. Does a combination product infringe the claim?Yes, potentially. The claim does not require monotherapy. Administration of the claimed compound with another cancer treatment can satisfy the claim if the compound is administered in an effective amount for breast cancer. Is a generic applicant automatically blocked by this patent?No. A method patent does not automatically block all generic manufacture or sale. The analysis depends on Orange Book listing, the proposed label, any section viii carve-out, other patents, and the applicant’s Paragraph IV position. Can the patent be enforced after its expiration date?No surviving claim can ordinarily be enforced after the patent term ends. Later-expiring patents covering the compound, formulation, salt, polymorph, manufacturing process, or a separate treatment regimen may continue to affect market entry. References
More… ↓ |
Drugs Protected by US Patent 7,982,043
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,982,043
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2005028443 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
